Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP-C: Truvada pre-exposure prophylaxis for natural conception in HIV-serodiscordant couples
2014-003874-17Phase 3Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Primary acceptability endpoint. Started Sep 2014; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-003874-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003874-17.